<?xml version='1.0' encoding='utf-8'?>
<document id="27154174"><sentence text="A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib."><entity charOffset="208-218" id="DDI-PubMed.27154174.s1.e0" text="vismodegib" /></sentence><sentence text="The Hedgehog pathway inhibitor vismodegib exhibits pH-dependent solubility, and in vitro studies have shown that vismodegib is a substrate of P-glycoprotein (P-gp) and is metabolized by cytochrome P450 (CYP) 2C9 and 3A4" /><sentence text=" The objective of this four-arm parallel study in healthy subjects was to evaluate the effect of the proton-pump inhibitor rabeprazole, the P-gp/CYP3A4 inhibitor itraconazole, and the CYP2C9 and 3A4 inhibitor fluconazole on vismodegib steady-state pharmacokinetics"><entity charOffset="123-134" id="DDI-PubMed.27154174.s3.e0" text="rabeprazole" /><entity charOffset="162-174" id="DDI-PubMed.27154174.s3.e1" text="itraconazole" /><entity charOffset="209-220" id="DDI-PubMed.27154174.s3.e2" text="fluconazole" /><entity charOffset="224-234" id="DDI-PubMed.27154174.s3.e3" text="vismodegib" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e0" e2="DDI-PubMed.27154174.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e0" e2="DDI-PubMed.27154174.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e0" e2="DDI-PubMed.27154174.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e0" e2="DDI-PubMed.27154174.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e1" e2="DDI-PubMed.27154174.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e1" e2="DDI-PubMed.27154174.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e1" e2="DDI-PubMed.27154174.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e2" e2="DDI-PubMed.27154174.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27154174.s3.e2" e2="DDI-PubMed.27154174.s3.e3" /></sentence><sentence text="" /><sentence text="Cohorts included a control arm (n = 22), in which vismodegib 150 mg was administered once daily (QD) for 7 days, and 3 arms in which vismodegib was co-administered QD for 7 days with rabeprazole 20 mg (including a 4-day lead-in; n = 24); itraconazole 200 mg (n = 22); or fluconazole 400 mg (n = 22)"><entity charOffset="183-194" id="DDI-PubMed.27154174.s5.e0" text="rabeprazole" /><entity charOffset="238-250" id="DDI-PubMed.27154174.s5.e1" text="itraconazole" /><entity charOffset="271-282" id="DDI-PubMed.27154174.s5.e2" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.27154174.s5.e0" e2="DDI-PubMed.27154174.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27154174.s5.e0" e2="DDI-PubMed.27154174.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27154174.s5.e0" e2="DDI-PubMed.27154174.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27154174.s5.e1" e2="DDI-PubMed.27154174.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27154174.s5.e1" e2="DDI-PubMed.27154174.s5.e2" /></sentence><sentence text="" /><sentence text="Area under the vismodegib concentration-time curve from zero to 24 h (AUC0-24h) at steady state was lower with concomitant rabeprazole administration relative to vismodegib alone [geometric mean ratio (GMR), 86"><entity charOffset="15-25" id="DDI-PubMed.27154174.s7.e0" text="vismodegib" /><entity charOffset="123-134" id="DDI-PubMed.27154174.s7.e1" text="rabeprazole" /><pair ddi="false" e1="DDI-PubMed.27154174.s7.e0" e2="DDI-PubMed.27154174.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27154174.s7.e0" e2="DDI-PubMed.27154174.s7.e1" /></sentence><sentence text="2 (associated 90 % confidence interval [CI], 76" /><sentence text="1, 97" /><sentence text="7)]" /><sentence text=" There was no effect of itraconazole on steady-state exposure of vismodegib [GMR, 96"><entity charOffset="24-36" id="DDI-PubMed.27154174.s11.e0" text="itraconazole" /></sentence><sentence text="4 (90 % CI 84" /><sentence text="9, 109" /><sentence text="6)]" /><sentence text=" Co-administration with fluconazole increased vismodegib steady-state AUC0-24h [GMR, 130"><entity charOffset="24-35" id="DDI-PubMed.27154174.s15.e0" text="fluconazole" /></sentence><sentence text="9 (90 % CI 115" /><sentence text="2, 148" /><sentence text="7)]" /><sentence text=" Co-administration of rabeprazole, itraconazole, and fluconazole had similar effects on the exposure of unbound vismodegib and total vismodegib"><entity charOffset="22-33" id="DDI-PubMed.27154174.s19.e0" text="rabeprazole" /><entity charOffset="35-47" id="DDI-PubMed.27154174.s19.e1" text="itraconazole" /><entity charOffset="53-64" id="DDI-PubMed.27154174.s19.e2" text="fluconazole" /><entity charOffset="112-122" id="DDI-PubMed.27154174.s19.e3" text="vismodegib" /><entity charOffset="133-143" id="DDI-PubMed.27154174.s19.e4" text="vismodegib" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e0" e2="DDI-PubMed.27154174.s19.e0" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e0" e2="DDI-PubMed.27154174.s19.e1" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e0" e2="DDI-PubMed.27154174.s19.e2" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e0" e2="DDI-PubMed.27154174.s19.e3" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e0" e2="DDI-PubMed.27154174.s19.e4" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e1" e2="DDI-PubMed.27154174.s19.e1" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e1" e2="DDI-PubMed.27154174.s19.e2" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e1" e2="DDI-PubMed.27154174.s19.e3" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e1" e2="DDI-PubMed.27154174.s19.e4" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e2" e2="DDI-PubMed.27154174.s19.e2" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e2" e2="DDI-PubMed.27154174.s19.e3" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e2" e2="DDI-PubMed.27154174.s19.e4" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e3" e2="DDI-PubMed.27154174.s19.e3" /><pair ddi="false" e1="DDI-PubMed.27154174.s19.e3" e2="DDI-PubMed.27154174.s19.e4" /></sentence><sentence text="" /><sentence text="The results of this study suggest that vismodegib can be administered with acid-reducing agents and P-gp and CYP inhibitors without the risk of a clinically meaningful pharmacokinetic drug-drug interaction"><entity charOffset="39-49" id="DDI-PubMed.27154174.s21.e0" text="vismodegib" /></sentence><sentence text=" CLINICALTRIALS" /><sentence text="" /><sentence text="NCT01772290" /><sentence text="" /></document>